Profile
Sector:
HealthcareCountry:
IsraelIPO:
16 February 1982Website:
http://www.tevapharm.comNext earnings report:
06 November 2024Last dividends:
27 November 2017Next dividends:
N/APrice
regular market | 4 min agoDividend
Analysts recommendations
Institutional Ownership
TEVA Latest News
TEL AVIV, Israel and PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new patient- and physician-reported interim results from the Phase 4 IMPACT-TD Registry study, revealing differences between TD patients with a psychotic disorder and those with a mood disorder. The IMPACT-TD Registry is the largest study of its kind evaluating the holistic effects of TD, showing real-world treatment patterns and outcomes with once-daily AUSTEDO® XR® (deutetrabenazine) extended-release tablets and twice-daily AUSTEDO (deutetrabenazine) tablets. Teva also announced interim data from a patient-reported survey describing early, real-world experience with AUSTEDO XR. These findings are being presented at the Psych Congress 2024 taking place from October 29 – November 2 in Boston, MA.
TEL AVIV, Israel & PARSIPPANY, N.J., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new, positive data on social functioning and quality of life from the Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. In the acute treatment phase of the study (Period 1), TEV-'749 demonstrated significant improvement in social functioning and quality of life across multiple validated measures from baseline to week 8. The systemic safety profile of TEV-'749 was consistent with other approved oral formulations of olanzapine, with no new safety signals identified and no PDSS events reported to date.1 In addition, in vitro data and interim results from a Phase 1 study evaluating the pharmacokinetic characteristics of TEV-'749 validate that its route of administration and drug delivery technology may effectively address the risk of PDSS development.1 These studies, highlighting the patient focused outcomes, were presented at Psych Congress 2024 taking place from October 29 – November 2, 2024, in Boston, MA.
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
TEL AVIV, Israel, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals Industries Ltd. (NYSE: and TASE: TEVA) is responding to the European Decision following its investigation into the company's practices regarding COPAXONE® -- the standard-of-care treatment for multiple sclerosis – and announcing its intention to appeal the judgement and fine imposed.
Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing drugs on the market across multiple clinical segments, including cancer drugs. Debt to equity is high vs peers; however, debt is on a declining trend.
TEL AVIV, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the United States (U.S.) Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia® (denosumab).1
Here is how Teva Pharmaceutical Industries Ltd. (TEVA) and Adaptive Biotechnologies (ADPT) have performed compared to their sector so far this year.
TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate. This marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.
PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of the first and only generic version of Sandostatin®1 LAR Depot, in the United States.
TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
What type of business is Teva Pharmaceutical Industries Limited?
Teva Pharmaceutical Industries Limited is a multinational pharmaceutical company headquartered in Petah Tikva, Israel. The company specializes in producing generic drugs, active pharmaceutical ingredients, and to a lesser extent, proprietary drugs. The company ranks 16th in the list of the largest pharmaceutical manufacturers and 704th in the ranking of the largest global companies by Forbes Global 2000. Teva has 80 plants in its portfolio and operates in 60 countries. Teva is a member of the American Association of Pharmaceutical Researchers and Manufacturers.
What sector is Teva Pharmaceutical Industries Limited in?
Teva Pharmaceutical Industries Limited is in the Healthcare sector
What industry is Teva Pharmaceutical Industries Limited in?
Teva Pharmaceutical Industries Limited is in the Drug Manufacturers - Specialty & Generic industry
What country is Teva Pharmaceutical Industries Limited from?
Teva Pharmaceutical Industries Limited is headquartered in Israel
When did Teva Pharmaceutical Industries Limited go public?
Teva Pharmaceutical Industries Limited initial public offering (IPO) was on 16 February 1982
What is Teva Pharmaceutical Industries Limited website?
https://www.tevapharm.com
Is Teva Pharmaceutical Industries Limited in the S&P 500?
No, Teva Pharmaceutical Industries Limited is not included in the S&P 500 index
Is Teva Pharmaceutical Industries Limited in the NASDAQ 100?
No, Teva Pharmaceutical Industries Limited is not included in the NASDAQ 100 index
Is Teva Pharmaceutical Industries Limited in the Dow Jones?
No, Teva Pharmaceutical Industries Limited is not included in the Dow Jones index
When was Teva Pharmaceutical Industries Limited the previous earnings report?
No data
When does Teva Pharmaceutical Industries Limited earnings report?
The next expected earnings date for Teva Pharmaceutical Industries Limited is 06 November 2024